Norepinephrine transporter inhibitors and their therapeutic potential

Drugs of the Future

Volumn 29, Issue 12, 2004, Pages 1235-1244

  Zhou, Jia ^a  

^a Acenta Discovery Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(2 METHOXYPHENOXY)PHENYLMETHYL]MORPHOLINE; AMFEBUTAMONE; AMOXAPINE; ATOMOXETINE; CONTRAST MEDIUM; DESIPRAMINE; DULOXETINE; FLUOXETINE; INDATRALINE; MAPROTILINE; MAZINDOL; METHYLNORETHYLREBOXETINE; MODAFINIL; NISOXETINE; NOCAINE; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PROTRIPTYLINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; THIONISOXETINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; CELL MEMBRANE; DEPRESSION; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG ACTIVITY; DRUG INHIBITION; DRUG STRUCTURE; HUMAN; INFECTION; INSOMNIA; MENTAL DISEASE; NAUSEA; NERVOUSNESS; NORADRENALIN RELEASE; NORADRENERGIC NERVE; POSITRON EMISSION TOMOGRAPHY; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; WEIGHT GAIN;

EID: 13544263446     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2004.029.12.855246     Document Type: Review

References (76)

1. Murray, C.J.L., Lopez, A.D. (Ed.). The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. Harvard University Press, Cambridge, 1996.
2. Rice, D.P., Miller, L.S. Health economics and cost implications of anxiety and other mental disorders in the United States. Br J Psychiatry 1998, 173: 4-9.
3. Greengard, P. The neurobiology of slow synaptic transmission. Science 2001, 294: 1024-30.
4. Gainetdinov, R.R., Sotnikova, T.D., Caron, M.G. Monoamine transporter pharmacology and mutant mice. Trends Pharmacol Sci 2002, 23: 367-73.
5. Sasaki-Adams, D.M., Kelley, A.E. Serotonin-dopamine interactions in the control of conditioned reinforcement and motor behavior. Neuropsychopharmacology 2001, 25: 440-52.
6. Carroll, F.I., Howell, L.L., Kuhar, M.J. Pharmacotherapies for treatment of cocaine abuse: Preclinical aspects. J Med Chem 1999, 42: 2721-36.
7. Olivier, B., Soudijn, W., van Wijngaarden, I. Serotonin, dopamine and norepinephrine transporters in the central nervous system and their inhibitors. Prog Drug Res 2000, 54: 59-119.
8. Zhou, J., Zhang, A., Kläß, T., Johnson, K.M., Wang, C.Z., Ye, Y., Kozikowski, A.P. Biaryl analogues of conformationally constrained tricyclic tropanes as potent and selective norepinephrine reuptake inhibitors: Synthesis and evaluation of their uptake inhibition at monoamine transporter sites. J Med Chem 2003, 46: 1997-2007.
9. 3,7]decanes: Thiophene analogues as potent norepinephrine transporter inhibitors. Bioorg Med Chem Lett 2003, 13: 3565-9.
10. Smith, M.P., Hoepping, A., Johnson, K.M., Trzcinska, M., Kozikowski, A.P. Dopaminergic agents for the treatment of cocaine abuse. Drug Discov Today 1999, 4: 322-32.
11. Smith, M.P., Johnson, K.M., Zhang, M., Flippen-Anderson, J.L., Kozikowski, A.P. Tuning the selectivity of monoamine transporter inhibitors by the stereochemistry of the nitrogen lone pair. J Am Chem Soc 1998, 120: 9072-3.
12. 3,7]-decanes as a novel class of serotonin transporter inhibitors. J Med Chem 2002, 45: 1930-41.
13. Fleishaker, J.C. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet 2000, 39: 413-27.
14. Wong, E.H.F., Sonders, M.S., Amara, S.G., Tinholt, P.M., Piercey, M.F.P., Hoffmann, W.P., Hyslop, D.K., Franklin, S., Porsolt, R.D., Bonsignori, A., Carfagna, N., McArthur, R.A. Reboxetine: A pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 2000, 47: 818-29.
15. Van Moffaert, M., Dierick, M. Noradrenaline (norepinephrine) and depression: Role in aetiology and therapeutic implications. CNS Drugs 1999, 12: 293-305.
16. Plewnia, C., Hoppe, J., Hiemke, C., Bartels, M., Cohen, L., Gerloff, C. Enhancement of human cortico-motoneuronal excitability by the selective norepinephrine reuptake inhibitor reboxetine. Neurosci Lett 2002, 330: 231-4.
17. Versiani, M., Cassano, G., Perugi, G., Benedetti, A., Mastalli, L., Nardi, A., Savino, M. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 2002, 63: 31-7.
18. Singh, S. Chemistry, design, and structure-activity relationship of cocaine antagonists. Chem Rev 2000, 100: 925-1024.
19. Axelrod, J. Regulation of the neurotransmitter norepinephrine. In: The Neurosciences. Third Study Program. Schmitt, F.O., Worden, F.G. (Eds.). MIT Press, Cambridge, 1974, 863-76.
20. Young, J.B., Landsberg, L. Catecholamines and the adrenal medulla. In: Williams Textbook of Endocrinology, 9th Ed. Wilson, J.D., Foster, D.W. (Eds.). W.B. Saunders Co., Philadelphia, 1998, 680-2.
21. Tellioglu, T, Robertson, D. Genetic or acquired deficits in the norepinephrine transporter: Current understanding of clinical implications. Exp Rev Mol Med 2001, http://www-ermm.cbcu. cam.ac.uk/01003878h.htm.
22. Pacholczyk, T., Blakely, R.D., Amara, S.G. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 1991, 350: 350-4.
23. Barker, E.L., Blakely, R.D. Norepinephrine and serotonin transporters: Molecular targets of antidepressant drugs. In: Psychopharmacology. A Fourth Generation of Progress. Bloom, F.E., Kupfer, D.J. (Eds.). Raven Press, New York, 1995, 321-33.
24. 3H-nisoxetine binding and norepinephrine transporter mRNA in SK-N-SHSY5Y cells. Brain Res Bull 1999, 49: 291-5.
25. Blakely, R.D., Bauman, A.L. Biogenic amine transporters: Regulation in flux. Curr Opin Neurobiol 2000, 10: 328-36.
26. Trendelenburg, U. The TiPS lecture: Functional aspects of the neuronal uptake of noradrenaline. Trends Pharmacol Sci 1991, 12: 334-7.
27. Amara, S.G., Sonders, M.S. Neurotransmitter transporters as molecular targets for addictive drugs. Drug Alcohol Depend 1998, 51: 87-96.
28. Millan, M.J., Gobert, A., Lejeune, F., Newman-Tancredi, A., Rivet, J.M., Auclair, A., Peglion, J.L. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 2001, 298: 565-80.
29. Wong, E.H.F., Ahmed, S., Marshall, R.C., McArthur, R., Taylor, D.P., Birgerson, L., Cetera, P. (Upjohn Co.). Highly selective norepinephrine reuptake inhibitors and methods of using the same. WO 0101973.
30. Melloni, P., Carniel, G., Della Torre, A., Bonsignori, A., Buonamici, M., Pozzi, O., Ricciardi, O., Rossi, A.C. Potential antidepressant agents, aryloxy-benzyl derivatives of ethanolamine and morpholine. Eur J Med Chem 1984, 19: 235-42.
31. 1 Database via the web site http://kidb.bioc.cwru.edu/pdsp.php.
32. Chumpradit, S., Kung, M.-P., Panyachotipun, C., Prapansiri, V., Foulon, C., Brooks, B.P., Szabo, S.A., Tejani-Butt, S., Frazer, A., Kung, H.F. Iodinated tomoxetine derivatives as selective ligands for serotonin and norepinephrine uptake sites. J Med Chem 1992, 35: 4492-7.
33. Gehlert, D.R., Hemrick-Luecke, S.K., Schober, D.A., Krushinski, J., Howbert, J.J., Robertson, D.W., Wong, D.T., Fuller, R.W. (R)-Thionisoxetine, a potent and selective inhibitor of central and peripheral norepinephrine uptake. Life Sci 1995, 56: 1915-20.
34. Bymaster, F.P., Katner, J.S., Nelson, D.L., Hemrick-Luecke, S.K., Threlkeld, P.G., Heiligenstein, J.H., Morin, S.M., Geniert, D.R., Perry K.W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002, 27: 699-711.
35. Sanchez, C., Hyttel, J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 1999, 19: 467-89.
36. Kinney, J.L., Evans, R.L. Jr. Evaluation of amoxapine. Clin Pharm 1982, 1: 417-24.
37. Barbaccia, M.L., Ravizza, L., Costa, E. Maprotiline: An antidepressant with an unusual pharmacological profile. J Pharmacol Exp Ther 1986, 236: 307-12.
38. Smith, N.C., Levi, R. LLC-PK (1) cells stably expressing the human norepinephrine transporter: A functional model of carrier-mediated norepinephrine release in protracted myocardial ischemia. J Pharmacol Exp Ther 1999, 291: 456-63.
39. Stahl, S.M., Pradko, J.F., Haight, B.R., Modell, J.G., Rockett, C.B., Learned-Coughlin, S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. J Clin Psychiatry 2004, 6: 159-66.
40. Boot, J.R., Brace, G., Delatour, C.L., Dezutter, N., Fairhurst, J., Findlay, J., Gallagher, P.T., Hoes, I., Mahadevan, S., Mitchell, S.N., Rathmell, R.E., Richards, S.J., Simmonds, R.G., Wallace L., Whatton M.A. Benzothienyloxy phenylpropanamines, novel dual inhibitors of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett 2004, 14: 5395-9.
41. Bymaster, F.P., Beedle, E.E., Findlay, J., Gallagher, P.T., Krushinski, J.H., Mitchell, S., Robertson, D.W., Thompson, D.C., Wallace L., Wong DT. Duloxetine (Cymbalta™), a dual inhibitor of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett 2003, 13: 4477-80.
42. Dubovsky, S.L. Beyond the serotonin reuptake inhibitors: Rationales for the development of new serotonergic agents. J Clin Psychiatry 1994, 55(Suppl.): 34-44.
43. Brunello, N., Racagni, G. Rationale for the development of noradrenaline reuptake inhibitors. Human Psychopharmacol 1998, 13: S13-9.
44. Hyttel, J., Larsen, J.J. Neurochemical profile of LU 19-005, a potent inhibitor of uptake of dopamine, noradrenaline and serotonin. J. Neurochem 1985, 44: 1615-22.
45. Hoepping, A., Johnson, K.M., George, C., Flippen-Anderson, J., Kozikowski, A.P. Novel conformationally constrained tropane analogues by 6-endo-trig radical cyclization and Stille coupling - Switch of activity toward the serotonin and/or norepinephrine transporter. J Med Chem 2000, 43: 2064-71.
46. Zhang, A., Zhou, G.C., Rong, S.-B., Johnson, K.M., Zhang, M., Kozikowski, A.P. Thiophene derivatives: A new series of potent norepinephrine and serotonin reuptake inhibitors. Bioorg Med Chem Lett 2002, 12: 993-5.
47. Kozikowski, A.P., Araldi, G.L., Boja, J., Meil, W.M., Johnson, K.M., Flippen-Anderson, J.L., George, C., Saiah, E. Chemistry and pharmacology of the piperidine-based analogues of cocaine. Identification of potent DAT inhibitors lacking the tropane skeleton. J Med Chem 1998, 41: 1962-9.
48. Woolverton, W.L., Ranaldi, R., Wang, Z., Ordway, G.A., Paul, I.A., Petukhov, P., Kozikowski, A.P. Reinforcing strength of a novel dopamine transporter ligand: Pharmacodynamic and pharmacokinetic mechanisms. J Pharmacol Exp Ther 2002, 303: 211-7.
49. Kozikowski, A.P., Johnson, K.M., Deschaux, O., Bandyopadhyay, B.C., Araldi, G.L., Carmone, G., Munzar, P., Smith, M.P., Balster, R.L., Beardsley, P.M., Tella, S.R. Mixed cocaine agonist/antagonist properties of (+)-methyl 4b-(4-chlorophenyl)-1-methylpiperidine-3a-carboxylate, a piperidine based analog of cocaine. J Pharmacol Exp Ther 2003, 305: 143-50.
50. Mignot, E., Nishino, S., Guilleminault, C., Dement, W.C. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994, 17: 436-7.
51. 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals. Eur J Pharmacol 1990, 180: 49-58.
52. Chemelli, R.M., Willie, J.T., Sinton, C.M., Elmquist, J.K., Scammel, T., Lee, C., Richardson, J.A., Williams, S.C., Xiong, Y., Kisanuki, Y., Fitch, T.E., Nakazato, M., Hammer, R.E., Saper, C.B., Yanagisawa, M. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 1999, 98: 437-51.
53. Ferraro, L., Tanganelli, S., O'Connor, W.T., Antonelli, T., Rambert, F., Fuxe, K. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol 1996, 306: 33-9.
54. Nishino, S., Mao, J., Sampathkumaran, R., Shelton, J., Mignot, E. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online 1998, 1: 49-61.
55. Wisor, J.P., Nishino, S., Sora, I., Uhl, G.H., Mignot, E., Edgar, D.M. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001, 21: 1787-94.
56. Zhou, J., He, R., Johnson, K.M., Ye, Y., Kozikowski A.P. Piperidine-based nocaine/modafinil hybrid ligands as highly potent monoamine transporter inhibitors: Efficient drug discovery by rational lead hybridization. J Med Chem 2004, 47: 5821-4.
57. Kando, J.C., Wells, B.G., Hayes, P.E. Depressive disorders. In: Drug Facts and Comparisons. Kastrup, E.K. (Ed.). Facts and Comparisons, St. Louis, 2004.
58. Stahl, S.M. Basic psychopharmacology of antidepressants, Part I: Antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998, 59(Suppl. 4): 5-14.
59. Page, M.E. The promises and pitfalls of reboxetine. CNS Drug Rev 2003, 9: 327-42.
60. Einarson, T.R., Addis, A., Mittmann, N., Iskedjian, M. Meta-analysis of venlafaxine, SSRIs and TCAs in the treatment of major depressive disorder. Can J Clin Pharmacol 1998, 5: 205-16.
61. Anttila, S., Leinonen, E. Duloxetine from Eli Lilly. Curr Opin Invest Drugs 2002, 3: 1217-21.
62. Simpson, D., Plosker, G.L. Atomoxetine: A review of its use in adults with attention deficit hyperactivity disorder. Drugs 2004, 64: 205-22.
63. Michelson, D., Adler, L., Spencer, T., Reimherr, F.W., West, S.A., Allen, A.J., Kelsey, D., Wernicke, J., Dietrich, A., Milton, D. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol Psychiatry 2003, 53: 112-20.
64. Inoue, S. Clinical studies with mazindol. Obesity Res 1995, 4: 549S-52S.
65. 3H]norepinephrine. J Pharmacol Exp Ther 2002, 302: 1113-22. For other details, see the web site: http://www.zyban.com/.
66. 11C-labeled desipramine and its metabolite 2-hydroxydesipramine: Potential radiotracers for PET studies of the norepinephrine transporter. Nucl Med Biol 1997, 24: 707-11.
67. Schou, M., Halldin, C., Pike, V., Sovago, J., Gulyas, B., Innis, B., Farde, L. Development of PET radioligands for the norepinephrine transporter. Eur J Nucl Med Mol Imag 2000, 29: S59.
68. 11 C]nisoxetine, a norepinephrine uptake inhibitor. Nucl Med Biol 1989, 16: 771-4.
69. Chumpradit, S., Kung, M.P., Panyachotipunm, C., Prapansiri, V., Foulon, C., Brooks, B.P., Szabo, S.A., Tejani-Butt, S., Frazer, A., Kung, H.F. Iodinated tomoxetine derivatives as selective ligands for serotonin and norepinephrine uptake sites. J Med Chem 1992, 35: 4492-7.
70. Gehlert, D.R., Schober, D.A., Hemrick-Luecke, S.K., Krushinski, J., Howbert, J.J., Robertson, D.W., Fuller, R.W., Wong, DT. Novel halogenated analogs of tomoxetine that are potent and selective inhibitors of norepinephrine uptake in brain. Neurochem Int 1995, 26: 47-52.
71. Wilson, A.A., Johnson, D.P., Mozley, D., Hussey, D., Ginovart, N., Nobrega, J., Garcia, A., Meyer, J., Houle, S. Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nucl Med Biol 2003, 30: 85-92.
72. 11C]MeNER. Nucl Med Biol 2003, 30: 707-14.
73. Ding, Y.S., Lin, K.S., Garza, V., Carter, P., Alexoff, D., Logan, J., Shea, C., Xu, Y., King, P. Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs. Synapse 2003, 50: 345-52.
74. Lin, K.S., Ding, Y.-S. Synthesis and evaluation of a new norepinephrine transporter PET ligand in nonhuman primates. J Label Comp Radiopharm 2003, 46(Suppl. 1): S58.
75. Kiyono, Y., Kanegawa, N., Kawashima, H., Fujiwara, H., Iida, Y., Nishimura, H., Saji, H. A new norepinephrine transporter imaging agent for cardiac sympathetic nervous function imaging: Radioiodinated (R)-N-methyl-3-(2-iodophenoxy)-3-phenylpropanamine. Nucl Med Biol 2003, 30: 697-706.
76. 125]iodo-nisoxetine to norepinephrine transporters in the brain. Nucl Med Biol 2004, 31: 533-41.